WMS-1 is under clinical development by WellMarker Bio and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I drugs for Pancreatic Cancer have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how WMS-1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

WMS-1 overview

WMS-1 is under development for the treatment of solid tumors including breast cancer, non-small cell lung cancer, colon cancer, bile duct cancer (cholangiocarcinoma), pancreatic cancer, head and neck cancer. It acts by targeting cetuximab-resistant gene (CRG). It is administered through oral route.

WellMarker Bio overview

WellMarker Bio, is manufactures and distributes drugs that produces biomarker-based cancer drugs and other related products. The company is headquartered in Republic of Korea (South Korea).

For a complete picture of WMS-1’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.